TLK2 promotes the proliferation, migration and invasion of human breast cancer cell lines

Abstract

Abstract: Objective To explore the effects of TLK2 in breast cancer (BC) cells and its possible mechanism. Methods Immunohistochemistry and Western blot were used to detect the expression of TLK2 in BC tissues and cell lines. RT-qPCR was employed to detect the expression of TLK2 mRNA and miR-622 in BC tissues and cell lines. CCK-8, BrdU and Transwell assays were used to detect the effects of TLK2 over-expression plasmid and miR-622 inhibitors on the proliferation, migration and invasion of HCC70 cells. The targeted regulatory relationship between miR-622 and TLK2 was predicted and verified by Target scanning online analysis database and dual-luciferase reporter gene, respectively. Results The expression of TLK2 in BC tissues or cell lines was significantly up-regulated (P＜0.05), and TLK2 significantly promoted the proliferation, migration and invasion of HCC70 cells (P＜0.01). The possible mechanism suggested that miR-622 can bind to the 3′UTR of TLK2. Conclusions TLK2 is involved in promoting the proliferation, migration and invasion of BC cells, and is negatively regulated by miR-622.

Key words: breast cancer, TLK2, miR-622

CLC Number:

R737.9

XIONG Yu-yuan, CHEN De-jie, MENG Lin, YAN Shan. TLK2 promotes the proliferation, migration and invasion of human breast cancer cell lines[J]. Basic & Clinical Medicine, 2021, 41(8): 1156-1162.

References

[1]Huang SY, Chen Y, Liang ZM, et al. Targeting Pin1 by all-trans retinoic acid (ATRA) overcomes tamoxifen resistance in breast cancer via multifactorial mechanisms[J]. Front Cell Dev Biol, 2019, 7: 322-337.
[2]Ma RM, Yang F, Huang DP, et al. The prognostic value of the expression of SMC4 mRNA in breast cancer[J]. Dis Markers, 2019, 2019: 2183057. doi: 10.1155/2019/2183057.
[3]Lin M, Yao Z, Zhao N, et al. TLK2 enhances aggressive phenotypes of glioblastoma cells through the activation of SRC signaling pathway[J]. Cancer Biol Ther, 2019, 20: 101-108.
[4]Segura-Bayona S, Stracker TH. The tousled-like kinases regulate genome and epigenome stability: implications in development and disease[J]. Cell Mol Life Sci, 2019, 76: 3827-3841.
[5]Kim ST, Ahn TJ, Lee E, et al. Exploratory biomarker analysis for treatment response in KRAS wild type metastatic colorectal cancer patients who received cetuximab plus irinotecan[J]. BMC Cancer, 2015, 15: 747-757.
[6]Kim JA, Tan Y, Wang X, et al. Comprehensive func-tional analysis of the tousled-like kinase 2 frequently amplified in aggressive luminal breast cancers[J]. Nat Commun, 2016, 7: 12991-13007.
[7]Silljé HH, Takahashi K, Tanaka K, et al. Mammalian homologues of the plant tousled gene code for cell-cycle-regulated kinases with maximal activities linked to ongoing DNA replication[J]. EMBO J, 1999, 18: 5691-5702.
[8]Kim JA, Anurag M, Veeraraghavan J, et al. Amplifica-tion of TLK2 Induces genomic instability via impairing the G2-M checkpoint[J]. Mol Cancer Res, 2016, 14: 920-927.
[9]Song Q, Pang H, Qi L, et al. Low microRNA-622 expression predicts poor prognosis and is associated with ZEB2 in glioma[J]. Onco Targets Ther, 2019, 12: 7387-7397.
[10]Li T, Sun X, Xu K. The suppressing role of miR-622 in renal cell carcinoma progression by down-regulation of CCL18/MAPK signal pathway[J]. Cell Biosci, 2018, 8: 17-24.
[11]Wang Y, Sun J, Wei X, et al. Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells[J]. Onco Targets Ther, 2017, 10:1091-1100.
[12]Liu C, Min L, Kuang J, et al. Bioinformatic identification of miR-622 Key target genes and experimental validation of the miR-622-RNF8 axis in breast cancer[J]. Front Oncol, 2019, 9: 1114-1150.

[1]	SU Lingfeng, WANG Huxia, WANG Yanfeng, SONG Zhangjun. Impact of chronic stress on the development of breast cancer [J]. Basic & Clinical Medicine, 2024, 44(9): 1303-1307.
[2]	XIA Yujia, YANG Zhenli, DAI Di, LIU Yuqin. Culture and characterization of breast cancer organoids [J]. Basic & Clinical Medicine, 2024, 44(9): 1223-1228.
[3]	LU Kai, LU Jianju, GUO Wenli, HUANG Jianqi, LI Zhihua. lncRNA VIM-AS5 expression and its effect on proliferation and migration of human breast cancer cell lines [J]. Basic & Clinical Medicine, 2024, 44(4): 447-453.
[4]	NAN Lu, GUO Menjie, GAO Yanan, JIA Hongyan. Research progress on the mechanism of annexin A family members in breast cancer [J]. Basic & Clinical Medicine, 2024, 44(3): 393-397.
[5]	Yiheliman·MAIMAITI, CAO Yanzhen, WANG Cuicui, YUE Na, LIANG Liping. Correlation between PIK3CA mutation and clinicopathological features and prognosis of breast cancer [J]. Basic & Clinical Medicine, 2024, 44(3): 303-307.
[6]	LI Jiangli, SUN Jing, TANG Yijun, GUO Junlan, CHEN Bo, GUO Shengnan. Circ-DDX5 inhibits the proliferation and invasion of human breast cancer cell lines by targeting miR-3940 [J]. Basic & Clinical Medicine, 2024, 44(1): 1-7.
[7]	CHEN Ning, PENG Tianying, ZHANG Weimiao, GAO Yanuo, LI Xuan, YAN Caizhen, LI Junxia. Synergistic pro-apoptotic effect of triptolide combined with doxorubicin in human breast cancer cell line MCF-7 [J]. Basic & Clinical Medicine, 2023, 43(8): 1186-1192.
[8]	WANG Jihui, CAO Jilie, ZHANG Lijun, ZHANG Jun, LU Wenbao. TARBP2 promotes human breast cancer cell metastasis by degrading AKAP12 transcript [J]. Basic & Clinical Medicine, 2023, 43(8): 1259-1264.
[9]	TANG Yijun, WANG Wenlong, LI Jiangli, YANG Huan, SUN Jing. LncRNA RP11-686D22.10 is related with the survival of breast cancer patients, affects the proliferation, invasion of breast cancer cell lines [J]. Basic & Clinical Medicine, 2023, 43(7): 1023-1029.
[10]	YANG Liangquan, YU Miao, JIANG Qian, ZHANG Minghui, YANG Haisong. miR-504 regulates proteasome activator and inhibits the proliferation and migration of breast cancer cell line MCF-7 [J]. Basic & Clinical Medicine, 2023, 43(1): 95-101.
[11]	WANG Qun, LI Xin, MA Jun, LI Wanming. Imaging of breast cancer targeted by the nucleic acid aptamer W3-quantum dots [J]. Basic & Clinical Medicine, 2023, 43(1): 76-82.
[12]	ZHANG Xiao-lei, LIU Jing, LI Chao-ping. Circ_0032821 is involved in sorafenib's inhibition of the proliferation, migration and invasion of breast cancer cell line T47D [J]. Basic & Clinical Medicine, 2022, 42(9): 1350-1354.
[13]	WANG Zi-yuan, DUAN Zhao-jun, LUO Yun-ping. Establishment and validation of lung-specific metastatic cell subline of mouse breast cancer [J]. Basic & Clinical Medicine, 2022, 42(7): 1083-1091.
[14]	HAN Xue-ying, CUI Feng, LI Jun. Deleted in breast cancer 1(DBC1) affects the sensitivity of breast cancer cell lines to etoposide [J]. Basic & Clinical Medicine, 2022, 42(7): 1060-1066.
[15]	KANG You-li, ZHAO Dan, DU Wen-jing, LI Li. SIRT5 promotes the proliferation of human breast cancer cells by regulating the succinylation of ALDH5A1 [J]. Basic & Clinical Medicine, 2022, 42(7): 1099-1107.